How Do You Value a Startup, Especially One With Little or No Revenue?

Early-stage startup valuation is not a single calculation. It is a negotiation anchored by a few defensible methods. For pre-revenue companies, investors and founders typically use the Berkus method or a scorecard, then cross-check the result with the venture capital (VC) method and market comparables. For companies with early revenue, the VC method and revenue multiples become more reliable. Discounted cash flow (DCF) is usually reserved for later stages where cash flows can be forecast with some confidence. The right method depends on stage, sector, and the purpose of the valuation (fundraising, option grants, or internal planning).

Pre-money vs. post-money: the number that actually matters in a term sheet

Founders often quote a valuation without specifying which one. This causes real confusion in negotiations.

• Pre-money valuation is the value of the company before new money comes in.
• Post-money valuation = pre-money + the amount invested.

If an investor puts in $2M at a $8M pre-money valuation, the post-money is $10M, and the investor owns 20% ($2M / $10M).

Why this matters: term sheets and dilution math are usually built on pre-money. A "$10M valuation" can mean very different ownership outcomes depending on which figure is being referenced. Always confirm which one is being discussed before comparing offers.

Matching the method to the stage

For biotech and life sciences specifically, valuation often leans on licensing and deal comparables rather than revenue multiples, because clinical-stage companies may have no product revenue at all. Databases of licensing deals and partnering transactions are commonly used as sanity checks in this sector.

The VC method, step by step

The VC method works backward from a future exit to today's value. It is the most common framework for early-stage fundraising.

1. Forecast an exit value. Estimate what the company could be worth at exit (typically 5–7 years out). This can be based on comparable acquisitions, projected revenue at exit multiplied by a sector multiple, or a target IPO value.
2. Apply the expected return multiple. A VC targeting a 10x return on a high-risk early-stage deal will divide the exit value by 10. This reflects the risk and the fund's return requirements.
3. Discount back to today. The result is the post-money valuation the VC needs to hit their target return. Subtract the investment amount to get the pre-money.

Example: A company forecasts a $100M exit in 5 years. The investor requires a 10x return. Post-money target = $100M / 10 = $10M. If the investor puts in $2M, the pre-money is $8M.

The return multiple is the key judgment call. It reflects stage, sector, and the fund's own strategy. Earlier and riskier deals demand higher multiples.

Adjusting for dilution, option pools, and future rounds

A target return multiple is not the same as the founder's outcome. Two adjustments are often overlooked:

• Dilution from future rounds. If the company will raise additional rounds before exit, the current investor's ownership will be diluted. The VC method should account for this by either using a higher required multiple or explicitly modeling future dilution.
• Option pool. Investors often require an option pool to be created or expanded before the investment (pre-money). This dilutes existing shareholders, not the new investor. The size of the pool (often 10–20% for early-stage) directly affects the effective pre-money valuation.

Ignoring either of these can make a headline valuation look better than the actual economic outcome for founders.

Sanity checks: comparables and deal data

No single method should stand alone. Cross-check the VC method result against:

• Comparable company valuations — what similar-stage companies in the same sector have raised at recently.
• Comparable transactions — acquisition prices for similar companies.
• Licensing and partnering deals — especially relevant in biotech, pharma, and life sciences, where deal terms (upfront payments, milestones, royalties) provide real market signals.

In sectors like biotech and life sciences, where revenue is often years away, these deal-based benchmarks are frequently more informative than revenue multiples. Venture Valuation, for example, specializes in independent assessments in biotech/life sciences and operates Biotechgate, a business development database covering global licensing deals and opportunities.

Common pitfalls

• Double-counting risk. If you apply a high discount rate and a high return multiple, you may be penalizing the same risk twice. Pick one consistent framework.
• Ignoring dilution. A valuation that looks strong today can shrink significantly after two more rounds.
• Over-relying on one method. The VC method, scorecard, and comparables each capture different things. Use at least two and explain the gap.
• Confusing pre-money and post-money. This is the most common source of disagreement in term sheet discussions.
• Using DCF too early. For pre-revenue companies, DCF requires assumptions that are essentially guesses. It is better suited to later stages.

What to do next

If you are preparing for a raise:

1. Identify your stage and pick two methods (e.g., scorecard + VC method for pre-revenue).
2. Build the VC method with explicit assumptions: exit value, return multiple, dilution, and option pool.
3. Gather 5–10 comparables from your sector, including licensing deals if you are in biotech or life sciences.
4. Present a range, not a single number, and be ready to explain the assumptions behind it.

The goal is not to find the "true" value. It is to build a defensible, transparent case that both sides can negotiate from.